Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis

BACKGROUND: At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9–12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tack, Ilse, Dumicho, Asnake, Ohler, Liesbet, Shigayeva, Altynay, Bulti, Abera Balcha, White, Kenneth, Mbatha, Mduduzi, Furin, Jennifer, Isaakidis, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563184/
https://www.ncbi.nlm.nih.gov/pubmed/33372989
http://dx.doi.org/10.1093/cid/ciaa1894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563184/
https://www.ncbi.nlm.nih.gov/pubmed/33372989
http://dx.doi.org/10.1093/cid/ciaa1894

Ejemplares similares